BlossomHill Courts Investors With Lung Cancer Drug
The San Diego biotech's investigational EGFR inhibitor is still in clinical development, with no efficacy results disclosed in this announcement.
Updated on Nov. 3, 2026 in Biotech
BlossomHill Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company (ticker BLSM), announced it will participate in Guggenheim's 3rd Annual Healthcare Innovations Conference in Boston. Its management will hold a fireside chat on November 10, 2026, and take part in one-on-one investor meetings; this is a corporate event, not a product launch.
Why it matters
Investor engagement at a major healthcare conference is a standard step for a clinical-stage drug developer that needs capital to advance its pipeline. The company's lead asset, BH-30643, is still investigational, so the event is about funding and visibility rather than any new clinical result.
The notice is a scheduling announcement, so it contains no performance metrics. The relevant technical reference is BH-30643, an investigational OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, which has received Fast Track designation for the C797S resistance population after third-generation EGFR TKI treatment. The source does not report efficacy figures for it.
The players
BlossomHill Therapeutics, Inc.
A Nasdaq-listed (BLSM) clinical-stage biopharmaceutical company headquartered in San Diego, focused on oncology drugs led by its investigational EGFR inhibitor BH-30643.
J. Jean Cui, Ph.D.
Founder and leader of BlossomHill Therapeutics, whose oncology work has contributed to three FDA-approved drugs.
Guggenheim
Financial services firm that hosts the annual Healthcare Innovations Conference, which connects healthcare companies with investors.
The details
BlossomHill is developing BH-30643, a drug designed to block the EGFR protein, a signaling receptor that drives growth in some lung cancers. The C797S mutation is a genetic change that can make tumors resistant to third-generation EGFR tyrosine kinase inhibitors (drugs that switch off EGFR's enzymatic activity). Fast Track designation is an FDA program that speeds review for drugs addressing serious conditions with unmet need. The conference appearance is a conversation with investors about how the company plans to fund and advance this program.
Timeline
November 3, 2026: BlossomHill announced its participation in the conference.
November 10, 2026, 3:00 pm Eastern Time: Management holds a fireside chat.
For 90 days after the chat: An archived replay remains available on BlossomHill's website.
The Tech Race
BH-30643 is an investigational OMNI-EGFR inhibitor aimed at the C797S resistance population that emerges after third-generation EGFR TKI treatment. The source does not place it against named competing programs, so its position in the field-level race cannot be assessed from this notice.
The conference appearance does not change any product or treatment available to patients today. Patients and clinicians would see practical effects only if BH-30643 later advances through clinical trials and regulatory review, a timeline the source does not state.
The takeaway
Watch the November 10, 2026 fireside chat for any disclosure of BH-30643's clinical plans or financing strategy. Because the source contains no clinical data, the next verifiable milestone will be a trial or regulatory announcement from BlossomHill.
What happens next
The fireside chat takes place on November 10, 2026, at 3:00 pm Eastern Time, with an audio webcast on BlossomHill's Events & Presentations page and a replay available for 90 days.
Further reading
For more on the research behind companies like this, explore the Biotech section.
